Skip to main content
ZNTL
NASDAQ Life Sciences

Zentalis Pharmaceuticals Reports Reduced Q1 Net Loss and Confirms Late 2027 Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.28
Mkt Cap
$303.585M
52W Low
$1.13
52W High
$6.95
52W Position info
279% above low
Off High info
38% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.13 on light trading volume (0.2× avg).

Summary

Zentalis Pharmaceuticals announced Q1 2026 financial results showing a reduced net loss and a cash runway into late 2027, alongside updates on its pivotal oncology clinical trials.


Key Events · Earnings and Guidance · ZNTL

  • Reduced Q1 Net Loss

    Reported a net loss of $(35.352) million for Q1 2026, a significant improvement from $(48.279) million in Q1 2025.

  • Maintained Cash Runway

    Ended Q1 2026 with $211.8 million in cash, cash equivalents, and marketable securities, providing funding into late 2027.

  • Pivotal Dose Confirmed

    Reaffirmed the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).

  • Phase 3 ASPENOVA Initiated

    Announced the dosing of the first patient in the confirmatory Phase 3 ASPENOVA clinical trial for azenosertib.


Analysis · ZNTL · Life Sciences

Zentalis Pharmaceuticals reported a significant reduction in its net loss for Q1 2026 and confirmed a strong cash position, extending its runway into late 2027. This financial stability is crucial for a clinical-stage biotech as it continues to advance its lead oncology asset, azenosertib, through pivotal trials. The company reiterated key clinical milestones, including the initiation of its Phase 3 ASPENOVA trial and the anticipated year-end 2026 topline readout for the DENALI Part 2 trial, which could support accelerated approval.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $4.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $303.6M. The 52-week trading range was $1.13 to $6.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.40 info
Change: -$0.340 (-20%) info
Market Cap: $133.642M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.40 info
Change: -$0.910 (-39%) info
Market Cap: $133.642M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.40 info
Change: -$0.885 (-39%) info
Market Cap: $133.642M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.40 info
Change: -$0.710 (-34%) info
Market Cap: $133.642M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.40 info
Change: -$2.42 (-63%) info
Market Cap: $133.642M info